 |
8 Diseases |  |
1 Trial |
|
1 Trial |  |
13 News |  |
- | domagrozumab (PF-06252616) / Pfizer, landogrozumab (LY2495655) / Eli Lilly, bimagrumab (BYM338) / Novartis, Eli Lilly
Journal: Simultaneous detection of myostatin-targeting monoclonal antibodies in dried blood spots and plasma using liquid chromatography-tandem mass spectrometry with field asymmetric ion mobility spectrometry. (Pubmed Central) - Nov 5, 2024
Recovery was 31.6-49.8?% for DBS and 51.4-85.3?% for plasma, with no significant matrix effect. This study provides an effective method for doping analysis and novel protein detection.
- | LY2495655 / Eli Lilly
Clinical, P2 data, Journal: LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. (Pubmed Central) - Sep 14, 2019
In the intention-to-treat analysis, LY2495655 did not confer clinical benefit in pancreatic cancer. Our data highlight the importance of assessing survival when investigating therapeutic management of cachexia and support the use of WL as a stratifier (independent of performance status).
- |||| landogrozumab (LY2495655) / Eli Lilly
Trial completion, Metastases: A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer (clinicaltrials.gov) - Mar 11, 2016
P2, N=125, Completed, Sponsor: Eli Lilly and Company
Our data highlight the importance of assessing survival when investigating therapeutic management of cachexia and support the use of WL as a stratifier (independent of performance status). Active, not recruiting --> Completed
- | landogrozumab (LY2495655) / Eli Lilly
Trial completion, Metastases: A Dose-Escalation Study in Participants With Advanced Cancer (clinicaltrials.gov) - Feb 9, 2016
P1, N=32, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || landogrozumab (LY2495655) / Eli Lilly
Trial primary completion date, Metastases: A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer (clinicaltrials.gov) - Jun 22, 2014
P2, N=120, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Trial primary completion date: Jul 2014 --> Oct 2014
- landogrozumab (LY2495655) / Eli Lilly
Enrollment closed, Metastases: A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer (clinicaltrials.gov) - Mar 16, 2014
P2, N=120, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jul 2014 --> Oct 2014 Recruiting --> Active, not recruiting
- |||| landogrozumab (LY2495655) / Eli Lilly
Trial completion: A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement (clinicaltrials.gov) - Mar 6, 2014
P2, N=384, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| landogrozumab (LY2495655) / Eli Lilly
Trial completion: A Study in Older Participants Who Have Fallen and Have Muscle Weakness (clinicaltrials.gov) - Dec 18, 2013
P2, N=172, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- landogrozumab (LY2495655) / Eli Lilly
Enrollment closed, Metastases: A Dose-Escalation Study in Participants With Advanced Cancer (clinicaltrials.gov) - Jul 31, 2012
P1, N=32, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | landogrozumab (LY2495655) / Eli Lilly
Trial completion: A Study of LY2495655 in Healthy Subjects (clinicaltrials.gov) - May 29, 2012
P1, N=44, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| landogrozumab (LY2495655) / Eli Lilly
New P2 trial: A Study in Older Participants Who Have Fallen and Have Muscle Weakness (clinicaltrials.gov) - May 21, 2012
P2, N=172, Completed, Sponsor: Eli Lilly and Company
- | landogrozumab (LY2495655) / Eli Lilly
New P1 trial, Metastases: A Dose-Escalation Study in Participants With Advanced Cancer (clinicaltrials.gov) - Jan 30, 2012
P1, N=32, Active, not recruiting, Sponsor: Eli Lilly and Company
- | landogrozumab (LY2495655) / Eli Lilly
New P2 trial, Metastases: A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer (clinicaltrials.gov) - Jan 4, 2012
P2, N=120, Active, not recruiting, Sponsor: Eli Lilly and Company